Results 81 to 90 of about 231,116 (154)

Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape

Immunotherapy has become a fourth pillar of cancer therapy, alongside surgery, radiotherapy and chemotherapy. Cancer immunotherapy seems to be most effective in the context of low but not negligible tumour burden, thus in the neoadjuvant setting before ...
Fallarino, Francesca, Blank, Christian U.   +1 more
core   +1 more source

Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB–IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study

Thoracic Cancer
Background Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non‐small cell lung cancer (NSCLC).
Chun‐Quan Liu, Kang‐Shun Guo, Qi Qin, Liu Yang, Yong Cui, Mu Hu   +5 more
doaj   +1 more source

Efficacy and Safety of Perioperative Immunotherapy for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Current Oncology
Background: The objective of this study is to indirectly compare the efficacy and safety of all currently available neoadjuvant chemoimmunotherapy and perioperative chemoimmunotherapy in randomized controlled trials (RCTs) involving patients with ...
Zhijuan Du, Siyuan Chen, Yuhui Qin, Yahui Lv, Xiangyu Du, Heying Yu, Zhefeng Liu   +6 more
doaj   +1 more source

Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?

, 2022
The development of immune checkpoint inhibitors (ICI) offers novel treatment possibilities for solid cancers, with the crucial benefit of providing higher cure rates.
Kabiljo, Julijan, Walczak, Henning, Bergmann, Michael, Zirnbauer, Rebecca, Laengle, Johannes, Petricevic, Branka   +5 more
core  

miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55

Scientific Reports
Genetic assessment of tumors following neoadjuvant immunotherapy helps identifying targets that mediate anti-tumor immunity. In this study, we explored dysregulated RNAs in esophageal squamous cell carcinoma samples after neoadjuvant immunotherapy using ...
Yang Pengjie, Jia Rong, Ning Pengfei
doaj   +1 more source

Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer

Frontiers in Immunology
BackgroundIn recent years, there has been significant research interest in immunotherapy for colorectal cancer (CRC). Specifically, immunotherapy has emerged as the primary treatment for patients with mismatch repair gene defects (dMMR) or microsatellite
Zijian Deng, Yajun Luo, Xiaoli Chen, Tao Pan, Yuanyi Rui, Hai Hu, Jin Yan, Ke Zhang, Cheng Luo, Bo Song   +9 more
doaj   +1 more source

Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies

Therapeutic Advances in Medical Oncology
Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its ...
Yuzhu Chen, Fei Qi, Chenhao Sun, Peng Jiang, Xiangyu Xue, Xiaomei Yang, Xiaomi Li, Xin He, Yishuo Wang, Tongmei Zhang   +9 more
doaj   +1 more source

Image_8_Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.tif

BackgroundNeoadjuvant therapy for resectable gastric cancer/gastroesophageal junction tumors is progressing slowly. Although immunotherapy for advanced gastric cancer/gastroesophageal junction tumors has made great progress, the efficacy and safety of ...
Zhengxiao Zhang (9260121), Guangxin Zhang (107025), Haiping Guo (292959), Yinghao Zhao (739173), Chengyan Jin (3993488), Xueying Liu (344877), Jindong Li (534123), Ti Tong (4333033), Jincheng Wang (257684)   +8 more
core   +1 more source

Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET-CT-based study. [PDF]

ESMO Open
Pan Y, Chen J, Lin H, Tang LB, Yan HH, Zeng JX, Dong S, Yan LX, Yang Y, Li DJ, Wu YL.   +10 more
europepmc   +1 more source

Image_6_Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.tif

BackgroundNeoadjuvant therapy for resectable gastric cancer/gastroesophageal junction tumors is progressing slowly. Although immunotherapy for advanced gastric cancer/gastroesophageal junction tumors has made great progress, the efficacy and safety of ...
Zhengxiao Zhang (9260121), Guangxin Zhang (107025), Haiping Guo (292959), Yinghao Zhao (739173), Chengyan Jin (3993488), Xueying Liu (344877), Jindong Li (534123), Ti Tong (4333033), Jincheng Wang (257684)   +8 more
core   +1 more source